Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $6 | $451 |
| % Growth | – | -100% | -98.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $6 | $451 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $60,917 | $41,129 | $39,162 | $24,344 |
| G&A Expenses | $22,613 | $17,968 | $21,536 | $17,210 |
| SG&A Expenses | $22,613 | $17,968 | $21,536 | $17,210 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$42 | $6 | -$44 |
| Operating Expenses | $83,530 | $59,097 | $60,698 | $41,554 |
| Operating Income | -$82,605 | -$59,097 | -$60,698 | -$33,728 |
| % Margin | – | – | -1,011,633.3% | -7,478.5% |
| Other Income/Exp. Net | $7,461 | $1,540 | $6 | $7,826 |
| Pre-Tax Income | -$75,144 | -$57,557 | -$60,692 | -$33,277 |
| Tax Expense | $0 | -$1,540 | -$2,277 | -$8,321 |
| Net Income | -$75,144 | -$57,557 | -$60,692 | -$33,277 |
| % Margin | – | – | -1,011,533.3% | -7,378.5% |
| EPS | -3.96 | -5.07 | -5.31 | -3.2 |
| % Growth | 21.9% | 4.5% | -65.9% | – |
| EPS Diluted | -3.96 | -5.07 | -5.5 | -3.2 |
| Weighted Avg Shares Out | 18,975 | 11,044 | 11,008 | 10,365 |
| Weighted Avg Shares Out Dil | 18,975 | 11,044 | 11,008 | 10,365 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,467 | $1,582 | $19 | $490 |
| Interest Expense | -$12 | $1,582 | $0 | $0 |
| Depreciation & Amortization | $0 | $2,612 | $2,277 | -$13,836 |
| EBITDA | -$82,605 | -$53,363 | -$60,698 | -$47,564 |
| % Margin | – | – | -1,011,633.3% | -10,546.3% |